Actinium Pharmaceuticals, Inc. ATNM.OB is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium and bismuth and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company s lead radiopharmaceutical Iomab TM B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase clinical study of Iomab B in refractory and relapsed Acute Myeloid Leukemia AML patients over the age of with a primary endpoint of durable complete remission. The company s second program, Actimab A, is continuing its clinical development in a Phase / trial for newly diagnosed AML patients over the age of in a single arm multicenter trial.
Quote | Actinium Pharmaceuticals Inc. (NYSE:ATNM)
Last: | $8.28 |
---|---|
Change Percent: | 0.23% |
Open: | $8.65 |
Close: | $8.28 |
High: | $8.75 |
Low: | $8.2401 |
Volume: | 181,755 |
Last Trade Date Time: | 06/09/2023 03:00:00 am |
News | Actinium Pharmaceuticals Inc. (NYSE:ATNM)
Actinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes PR Newswire NEW YORK , June 7, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, t...
2023-05-24 13:57:04 ET The Russell 3000 index will have a new look on June 26, after the market opens, when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added an...
Message Board Posts | Actinium Pharmaceuticals Inc. (NYSE:ATNM)
Subject | By | Source | When |
---|---|---|---|
Been watching the share price and have to | timberwolf7 | investorshub | 04/11/2023 4:24:43 AM |
whytestocks: $ATNM News Article - Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Po | whytestocks | investorshangout | 02/27/2023 1:05:46 PM |
Results were definitely FDA approvable. Everyone is | Pharmboy46 | investorshub | 02/22/2023 6:38:21 PM |
What's wrong? I don't understand! Down 5$ in | blukky | investorshub | 02/22/2023 6:26:34 PM |
PUMP & DUMP | Lonewolf1 | investorshub | 02/21/2023 9:41:37 PM |